Objective:
To evaluate the efficacy and safety of a subcutaneous formulation of teprotumumab (TEPEZZA) in patients with moderate-to-severe active thyroid eye disease (TED).
Key Findings:
- 77% of patients receiving subcutaneous TEPEZZA achieved a proptosis response at 24 weeks compared to 19.6% in the placebo group.
- Mean proptosis reduction was −3.17 mm at week 24.
- Statistically significant improvements were observed in overall responder rates, Clinical Activity Score (CAS), diplopia outcomes, and quality of life measures.
Interpretation:
The subcutaneous formulation of TEPEZZA offers comparable efficacy to the intravenous version while enhancing convenience for patients.
Limitations:
- Improvements in visual functioning scores did not reach statistical significance.
- Full data from the trial are pending presentation at a medical congress.
Conclusion:
If confirmed, subcutaneous TEPEZZA could significantly enhance TED management, providing a more flexible treatment option for patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
